A Phase I/IIa Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients With Advanced, Unresectable Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 14 Jun 2016
Price : $35 *
At a glance
- Drugs PLX 8394 (Primary)
- Indications Hairy cell leukaemia; Malignant melanoma; Solid tumours; Thyroid cancer
- Focus Adverse reactions
- Sponsors Plexxikon
- 31 Aug 2018 Biomarkers information updated
- 15 Sep 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 18 Apr 2014 Planned number of patients changed from 42 to 172 as reported by ClinicalTrials.gov record.